Antitumor activity and efficacy of shorter versus longer duration of anthracycline-taxane neoadjuvant chemotherapy in stage II-III HER2-negative breast cancer: a 10-year, retrospective analysis.
Riccardo LobefaroEmma ZattarinFederico NichettiMichele PrisciandaroFrancesca LigorioMarta BrambillaPierangela SepeFrancesca CortiGiorgia PeverelliArianna OttiniTeresa BeninatoLaura MazzeoCarmen G ReaGabriella MarianiFilippo de BraudGiulia V BianchiClaudio VernieriGiuseppe CapriPublished in: Therapeutic advances in medical oncology (2020)
Shorter duration of neoadjuvant anthracycline-taxane ChT was not associated with worse clinical outcomes in patients with stage II-III BC. Prospective studies are needed to evaluate whether the duration of neoadjuvant anthracycline-taxane-based ChT can be reduced in specific patient subgroups without negatively affecting clinical outcomes.